BCRX

Business Context and Reporting Period

Company: BioCryst Pharmaceuticals, Inc. (BCRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: BioCryst is a global biotechnology company focused on developing and commercializing oral small-molecule and injectable protein therapeutics for rare diseases. Its primary commercial product is ORLADEYO® (berotralstat) for hereditary angioedema (HAE). The company also holds rights to RAPIVAB® (peramivir) for influenza and maintains a pipeline including BCX17725 (Netherton syndrome), avoralstat (diabetic macular edema), and complement inhibitors.

Key Financial Metrics

Note: Debt figures represent the carrying value of the Pharmakon Term Loan. Royalty financing obligations are recorded as liabilities on the balance sheet.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by $52.8 million (56.9%) year-over-year. This was driven primarily by a $45.4 million increase in ORLADEYO net revenue due to higher volume (strong patient demand and faster conversion from free to paid product) and price increases. Other revenues increased by $7.3 million, largely due to peramivir sales to the U.S. government.
• Profitability: The company reported a net income of $32,000 in Q1 2025, a significant improvement from a net loss of $35.4 million in Q1 2024. Operating income turned positive ($21.2 million) compared to an operating loss of $14.5 million in the prior year.
• Expense Management:
  • R&D Expenses: Decreased to $37.3 million from $46.5 million, primarily due to the discontinuation of the Factor D program and completion of major Berotralstat clinical activities.
  • Selling, General & Administrative (SG&A): Increased to $82.5 million from $59.5 million, driven by expanded commercial infrastructure for ORLADEYO and increased stock-based compensation.
• Cash Flow: Net cash used in operating activities improved significantly to $27.5 million from $53.7 million in the prior year, despite the net income, due to changes in working capital (specifically a decrease in accounts payable and accrued expenses).

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Liquidity: Management believes current financial resources (cash, cash equivalents, and investments totaling approx. $315.6 million) are sufficient to fund operations for at least the next 12 months.
• ORLADEYO Expansion: The company submitted an NDA to the FDA in May 2025 to expand the ORLADEYO label to pediatric patients aged 2 to 11 using an oral granule formulation. Regulatory filings in Europe, Japan, and Canada are also expected in 2025.
• Pipeline Progress:
  • BCX17725: FDA cleared the IND for a Phase 1 trial in the U.S. and Australia; initial data expected in 2025.
  • Avoralstat: First clinical trial authorized in Australia; initial data expected by end of 2025.

Risks and Contingencies:

• Patent Litigation: In January 2025, the company received a Paragraph IV notice from Annora Pharma regarding a generic version of ORLADEYO. BioCryst filed a patent infringement lawsuit in March 2025. The outcome is uncertain and could materially impact future revenues.
• Debt Covenants: The company is subject to restrictive covenants under the Pharmakon Loan Agreement. A breach could trigger an event of default, requiring immediate repayment of the outstanding principal.
• Government Contracts: Revenue from peramivir depends on the U.S. Government exercising optional ordering periods under a contract awarded in September 2024. There is no guarantee these options will be exercised.
• Profitability: The company has a history of operating losses and may never achieve sustained profitability. Future capital raises may be necessary.

Investor Verification Checklist

• Patent Litigation Status: Monitor the progress of the lawsuit against Annora Pharma and potential impacts on ORLADEYO exclusivity.
• Debt Prepayment: Verify the impact of the $75 million partial prepayment made on April 18, 2025, on the remaining debt balance and interest obligations.
• Pediatric NDA Approval: Track the FDA's decision on the NDA for the pediatric oral granule formulation of ORLADEYO.
• Government Contract Execution: Confirm if the U.S. Government exercises the optional ordering periods for RAPIVAB under the ASPR contract.
• Royalty Financing Obligations: Review the effective interest rates and repayment schedules for the RPI and OMERS royalty financing agreements, as these significantly impact interest expense.